{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:42:42Z","timestamp":1794008562870,"version":"4.8.0"},"reference-count":39,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Ceralasertib is an oral ataxia telangiectasia and Rad3\u2013related (ATR) inhibitor with preclinical activity in ataxia-telangiectasia mutated (ATM)-altered cancers. The phase IIa PLANETTE study evaluated ceralasertib in previously treated advanced solid tumors (cohort A) or metastatic castration-resistant prostate cancer (cohort B) with ATM alterations (ATM mutations and\/or ATM protein deficiency).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Patients received ceralasertib 160 mg twice daily on days 1 to 14 of a 28-day cycle. Efficacy was evaluated in patients with centrally confirmed ATM alterations. The primary endpoint was objective response rate (ORR; cohort A) or composite response rate (CRR: radiographic response, prostate-specific antigen response, or circulating tumor cell conversion; cohort B). Secondary endpoints included progression-free survival (PFS) and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Cohorts A and B included 30 and 15 patients, respectively. ORR (cohort A) was 7.1% [80% confidence interval (CI), 1.9\u201317.9; n = 2\/28]: one complete response ongoing at 14.1 months (breast cancer) and one partial response ongoing at 7.4 months (endometrial cancer). CRR (cohort B) was 7.7% (80% CI, 0.8\u201328.6; n = 1\/13). In patients with centrally confirmed ATM protein loss, the ORR was 18.2% (80% CI, 4.9\u201341.5; n = 2\/11) and CRR was 0% (80% CI, 0\u201328; n = 0\/7). The median PFS was 3.7 months in each cohort (cohort A, 80% CI, 1.9\u20135.6; cohort B, 80% CI, 1.9\u2013not calculable). Grade \u22653 adverse events (AE) occurred in 50% of cohort A and 53.3% of cohort B patients. The most common AEs overall were asthenia\/fatigue, nausea, and anemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Ceralasertib monotherapy was tolerated; however, responses were limited. Alternative patient selection and combination treatments are being explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In the phase IIa PLANETTE study in advanced\/metastatic ATM-altered cancers, ceralasertib 160 mg twice daily (days 1\u201314, 28-day cycle) was tolerated; objective responses were limited, corroborating previous findings with ATR inhibitors in ATM-deficient tumors. Optimizing biomarker-based patient selection beyond ATM deficiency represents a key aspect of future ATR inhibitor development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0184","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T03:53:43Z","timestamp":1780286023000},"page":"1546-1556","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7003-7982","authenticated-orcid":false,"given":"Rahul","family":"Aggarwal","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, University of California, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-5351","authenticated-orcid":false,"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yw1f353","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Bergoni\u00e9 2 Department of Medicine, , Bordeaux, France."},{"name":"3Faculty of Medicine, University of Bordeaux, Bordeaux, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5914-7272","authenticated-orcid":false,"given":"Susan M.","family":"Domchek","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 4 Basser Center for BRCA, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0882-3621","authenticated-orcid":false,"given":"Oscar","family":"Goodman","sequence":"additional","affiliation":[{"name":"5Hematology\/Oncology, Nevada Oncology Specialists, Las Vegas, Nevada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5562-1857","authenticated-orcid":false,"given":"Sophie","family":"Postel-Vinay","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0321g0743","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Gustave Roussy 6 Drug Development Department, U981 INSERM Research Unit, , Villejuif, France."},{"name":"7Cancer Institute, University College of London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7731-3601","authenticated-orcid":false,"given":"Jesus","family":"Garcia-Donas","sequence":"additional","affiliation":[{"name":"8Gynecologic and Genitourinary Tumors, HM Hospitales \u2013 Centro Integral Oncol\u00f3gico HM Clara Campal, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5990-298X","authenticated-orcid":false,"given":"Tanya","family":"Dorff","sequence":"additional","affiliation":[{"name":"9Genitourinary Disease Program, City of Hope Comprehensive Cancer Center, Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0356-8796","authenticated-orcid":false,"given":"Zachery R.","family":"Reichert","sequence":"additional","affiliation":[{"name":"10University of Michigan, Rogel Comprehensive Cancer Center, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4455-557X","authenticated-orcid":false,"given":"Armelle","family":"Vinceneux","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01cmnjq37","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre L\u00e9on B\u00e9rard 11 Medical Oncology, , Lyon, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal","family":"Shore","sequence":"additional","affiliation":[{"name":"12START Carolinas\/Carolina Urologic Research Center, Myrtle Beach, South Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2653-4110","authenticated-orcid":false,"given":"Catherine H.","family":"Marshall","sequence":"additional","affiliation":[{"name":"13Oncology, Johns Hopkins University, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9005-7769","authenticated-orcid":false,"given":"Joshua","family":"Armenia","sequence":"additional","affiliation":[{"name":"14Oncology Data Science, AstraZeneca, Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1843-4809","authenticated-orcid":false,"given":"Graeme","family":"Parr","sequence":"additional","affiliation":[{"name":"15Oncology Early Development Clinical, AstraZeneca, Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8016-2840","authenticated-orcid":false,"given":"Aleksandra","family":"Kmieciak","sequence":"additional","affiliation":[{"name":"16Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6678-0072","authenticated-orcid":false,"given":"Natalia","family":"Lukashchuk","sequence":"additional","affiliation":[{"name":"17Translational Medicine, AstraZeneca, Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1650-2892","authenticated-orcid":false,"given":"Olga","family":"Murina","sequence":"additional","affiliation":[{"name":"17Translational Medicine, AstraZeneca, Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6063-1283","authenticated-orcid":false,"given":"Daniel","family":"Slade","sequence":"additional","affiliation":[{"name":"18Statistical Science, AstraZeneca, Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7534-2003","authenticated-orcid":false,"given":"Neel","family":"Shah","sequence":"additional","affiliation":[{"name":"19Oncology Early Development Clinical, AstraZeneca, Waltham, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2557-8170","authenticated-orcid":false,"given":"Bienvenu","family":"Loemb\u00e9","sequence":"additional","affiliation":[{"name":"15Oncology Early Development Clinical, AstraZeneca, Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9956-257X","authenticated-orcid":false,"given":"Emma","family":"Dean","sequence":"additional","affiliation":[{"name":"20Oncology Early Development, AstraZeneca, Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9615-7173","authenticated-orcid":false,"given":"Elhan","family":"Sanai","sequence":"additional","affiliation":[{"name":"15Oncology Early Development Clinical, AstraZeneca, Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9006-7043","authenticated-orcid":false,"given":"Wassim","family":"Abida","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 21 Genitourinary Oncology Service, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"2026070203265808500_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13045-019-0733-6","article-title":"Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand","volume":"12","author":"Mei","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2026070203265808500_bib2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","article-title":"Targeting ATR in patients with cancer","volume":"21","author":"Ngoi","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026070203265808500_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2018.03.005","article-title":"Targeting the replication stress response in cancer","volume":"188","author":"Forment","year":"2018","journal-title":"Pharmacol Ther"},{"key":"2026070203265808500_bib4","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/s41467-024-45996-4","article-title":"The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment","volume":"15","author":"Hardaker","year":"2024","journal-title":"Nat Commun"},{"key":"2026070203265808500_bib5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1535-7163.MCT-22-0685","article-title":"Selective inhibition of ATM-dependent double-strand break repair and checkpoint control synergistically enhances the efficacy of ATR inhibitors","volume":"22","author":"Turchick","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2026070203265808500_bib6","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","article-title":"Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a phase I study","volume":"27","author":"Yap","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026070203265808500_bib7","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.3390\/cancers15164195","article-title":"Relevance of ATM status in driving sensitivity to DNA damage response inhibitors in patient-derived xenograft models","volume":"15","author":"Karmokar","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026070203265808500_bib8","doi-asserted-by":"crossref","first-page":"190156","DOI":"10.1098\/rsob.190156","article-title":"A consensus set of genetic vulnerabilities to ATR inhibition","volume":"9","author":"Hustedt","year":"2019","journal-title":"Open Biol"},{"key":"2026070203265808500_bib9","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM mutations in cancer: therapeutic implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2026070203265808500_bib10","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1158\/1078-0432.CCR-23-1763","article-title":"Ataxia-telangiectasia mutated loss-of-function displays variant and tissue-specific differences across tumor types","volume":"30","author":"Pili\u00e9","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026070203265808500_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12885-021-09082-y","article-title":"Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets","volume":"22","author":"Lai","year":"2022","journal-title":"BMC Cancer"},{"key":"2026070203265808500_bib12","doi-asserted-by":"crossref","first-page":"1162644","DOI":"10.3389\/fonc.2023.1162644","article-title":"Impact of DNA damage repair alterations on prostate cancer progression and metastasis","volume":"13","author":"Lukashchuk","year":"2023","journal-title":"Front Oncol"},{"key":"2026070203265808500_bib13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2020.10.029","article-title":"Advanced prostate cancer with ATM loss: PARP and ATR inhibitors","volume":"79","author":"Neeb","year":"2021","journal-title":"Eur Urol"},{"key":"2026070203265808500_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"key":"2026070203265808500_bib15","doi-asserted-by":"crossref","first-page":"S482","DOI":"10.1016\/j.annonc.2024.08.686","article-title":"Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF)","volume":"35","author":"Carneiro","year":"2024","journal-title":"Ann Oncol"},{"key":"2026070203265808500_bib16","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"2026070203265808500_bib17","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","article-title":"Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells","volume":"39","author":"Lloyd","year":"2020","journal-title":"Oncogene"},{"key":"2026070203265808500_bib18","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.4143\/crt.2018.526","article-title":"Therapeutic targeting of the DNA damage response using an ATR inhibitor in biliary tract cancer","volume":"51","author":"Nam","year":"2019","journal-title":"Cancer Res Treat"},{"key":"2026070203265808500_bib19","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res"},{"key":"2026070203265808500_bib20","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1158\/1078-0432.CCR-21-0251","article-title":"Phase I study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026070203265808500_bib21","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1200\/PO.20.00439","article-title":"Ceralasertib-mediated ATR inhibition combined with olaparib in advanced cancers harboring DNA damage response and repair alterations (olaparib combinations)","volume":"5","author":"Mahdi","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2026070203265808500_bib22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy","volume":"33","author":"Kim","year":"2022","journal-title":"Ann Oncol"},{"key":"2026070203265808500_bib23","doi-asserted-by":"crossref","first-page":"e005041","DOI":"10.1136\/jitc-2022-005041","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer","volume":"10","author":"Kwon","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026070203265808500_bib24","doi-asserted-by":"crossref","first-page":"e175369","DOI":"10.1172\/JCI175369","article-title":"Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation","volume":"134","author":"Dillon","year":"2024","journal-title":"J Clin Invest"},{"key":"2026070203265808500_bib25","doi-asserted-by":"crossref","first-page":"CT006","DOI":"10.1158\/1538-7445.AM2022-CT006","article-title":"Abstract CT006: phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response (DDR) defects","volume":"18","author":"Yap","year":"2022","journal-title":"Cancer Res"},{"key":"2026070203265808500_bib26","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat Med"},{"key":"2026070203265808500_bib27","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","article-title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","volume":"30","author":"Besse","year":"2024","journal-title":"Nat Med"},{"key":"2026070203265808500_bib28","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1016\/j.annonc.2024.08.098","article-title":"90P Clonal haematopoiesis of indeterminate potential (CHIP) might mislead interpretation of ATM and CHEK2 alterations detected on liquid biopsies","volume":"35","author":"Rescigno","year":"2024","journal-title":"Ann Oncol"},{"key":"2026070203265808500_bib29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1200\/JCO.2025.43.5_suppl.221","article-title":"Equal-depth sequencing of white blood cells (WBC) and plasma from prostate cancer (PCa) liquid biopsies (LBx) and association with clonal hematopoiesis (CH) confounders in clinically relevant genes","volume":"43","author":"Antonarakis","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026070203265808500_bib30","doi-asserted-by":"crossref","first-page":"13837","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat Commun"},{"key":"2026070203265808500_bib31","doi-asserted-by":"crossref","first-page":"111081","DOI":"10.1016\/j.celrep.2022.111081","article-title":"Guiding ATR and PARP inhibitor combinationswith chemogenomic screens","volume":"40","author":"Zimmermann","year":"2022","journal-title":"Cell Rep"},{"key":"2026070203265808500_bib32","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1038\/s41388-018-0606-4","article-title":"Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"key":"2026070203265808500_bib33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1535-7163.MCT-21-0615","article-title":"RP-3500: a novel, potent, and selective ATR inhibitor that is effective in preclinical models as a monotherapy and in combination with PARP inhibitors","volume":"21","author":"Roulston","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2026070203265808500_bib34","doi-asserted-by":"crossref","first-page":"S583","DOI":"10.1016\/j.annonc.2021.08.1034","article-title":"Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies","volume":"32","author":"Aggarwal","year":"2021","journal-title":"Ann Oncol"},{"key":"2026070203265808500_bib35","doi-asserted-by":"crossref","first-page":"100814","DOI":"10.1016\/j.esmoop.2023.100814","article-title":"340 ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: results from the ENGOT\/GYN1\/NCRI ATARI trial","volume":"8","author":"Banerjee","year":"2023","journal-title":"ESMO Open"},{"key":"2026070203265808500_bib36","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1101\/gad.290957.116","article-title":"ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells","volume":"31","author":"Yazinski","year":"2017","journal-title":"Genes Dev"},{"key":"2026070203265808500_bib37","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"2026070203265808500_bib38","doi-asserted-by":"crossref","first-page":"CT267","DOI":"10.1158\/1538-7445.AM2025-CT267","article-title":"Abstract CT267: first results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic solid tumors","volume":"85","author":"Ulahannan","year":"2025","journal-title":"Cancer Res"},{"key":"2026070203265808500_bib39","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0184\/3799719\/crc-26-0184.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1546\/3809784\/crc-26-0184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1546\/3809784\/crc-26-0184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:29:09Z","timestamp":1782977349000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/7\/1546\/786365\/Ceralasertib-Monotherapy-in-Patients-with-ATM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0184","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32873519","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873546","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873579","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873558","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873555","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873534","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873567","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873528","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873537","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873549","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873582","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873561","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873564","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873531","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873543","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873576","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873540","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873573","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32873552","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8571635","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}